Expansion Opportunity LGM Pharma is rapidly expanding its U.S. manufacturing footprint with investments totaling at least $15 million across Texas and Colorado, including new capacity for niche high-value OSDs. This opens opportunities to position our API sourcing and CDMO services to align with their enhanced production capabilities and to supply critical APIs for their expanded lines.

Niche Dosage Demand Colorado Springs facility focus on oral solid dose products and orally disintegrating tablets signals rising demand for specialized formulations. A sales approach can highlight our expertise in deliverable API sourcing and regulatory support for high-value, complex dosage forms and new delivery technologies.

Regulatory-Ready Advantage LGM Pharma emphasizes full technical documentation and regulatory support for newly approved APIs and global regulatory approvals. Target initiatives can offer enhanced regulatory affairs services, risk assessment, and efficient supply chain mapping to accelerate time-to-market for clients’ APIs and products.

Integrated CDMO Reach With end-to-end capabilities spanning API sourcing, contract development, manufacturing, and market intelligence, LGM Pharma presents a one-stop solution. Sales opportunities exist for bundled offerings to CROs, biotech startups, and generic manufacturers seeking streamlined development-to-commercialization workflows.

Global Regulatory Network The established supplier network with approvals from US FDA, EDQM, TGA, MHRA, PMDA, and others creates a strong value proposition for global partners. Propose collaborations that leverage this regulatory access to reduce customer regulatory burden and enable faster international product launches.